Quad/Graphics, Inc. has a 12 month low of $4.06 and a 12 month high of $9.13. The company has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $6.40.

Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services ...

Regeneron Pharmaceuticals announced on Monday that it will acquire "substantially all" of genetic testing company 23andMe's assets. The pharmaceutical company said it won the court-supervised ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

Genetic testing company 23andMe filed for bankruptcy in March. Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Quad/Graphics had a negative net margin of 1.90% and a positive return on equity of 58.44%. As a group, research analysts anticipate that Quad/Graphics will post 1.08 EPS for the current fiscal year.

Quad/Graphics (QUAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.10 per share a year ago.

SUSSEX, Wis. (AP) — SUSSEX, Wis. (AP) — Quad/Graphics Inc. (QUAD) on Tuesday reported net income of $5.8 million in its first quarter. On a per-share basis, the Sussex, Wisconsin-based company ...